Introduction
The European Journal of Microbiology and Infectious Diseases (EJMID) is a peer‑reviewed, open‑access scientific periodical that publishes original research, reviews, case reports, and editorials covering all aspects of microbiology and infectious disease science. Since its launch in 1990, the journal has become a respected platform for microbiologists, clinicians, epidemiologists, and public‑health professionals across Europe and worldwide. By providing rapid, high‑quality dissemination of findings—from novel pathogen identification to antimicrobial‑resistance surveillance—EJMID plays a central role in shaping clinical practice, guiding policy, and advancing fundamental knowledge in the fight against infectious threats Turns out it matters..
In this article we will explore the journal’s scope, editorial process, and impact; break down how authors can handle the submission workflow; illustrate its influence with real‑world examples; examine the scientific principles that underlie the research it publishes; highlight common pitfalls for prospective contributors; and answer frequently asked questions. Whether you are a seasoned researcher seeking a reputable outlet for your work or a student curious about the publication landscape in microbiology, this guide will give you a comprehensive understanding of the European Journal of Microbiology and Infectious Diseases.
Detailed Explanation
Scope and Aims
EJMID covers a broad spectrum of topics that intersect microbiology and infectious disease medicine. Its aims are to:
- Disseminate cutting‑edge research on bacterial, viral, fungal, and parasitic pathogens, including their genetics, physiology, and host‑pathogen interactions.
- Promote translational studies that bridge laboratory discoveries with clinical applications, such as vaccine development, diagnostic innovations, and therapeutic strategies.
- allow surveillance and epidemiology of emerging and re‑emerging infections, antimicrobial‑resistance trends, and outbreak investigations.
- Encourage interdisciplinary dialogue among microbiologists, clinicians, immunologists, pharmacologists, and public‑health experts.
By embracing this wide remit, the journal attracts manuscripts ranging from molecular microbiology (e., CRISPR‑based gene editing in Staphylococcus aureus) to population‑level studies (e.g.But g. , multi‑country analyses of carbapenem‑resistant Enterobacteriaceae prevalence).
Editorial Structure
The editorial board consists of renowned scholars representing diverse sub‑disciplines and geographic regions. Plus, at the helm is the Editor‑in‑Chief, who oversees policy, ensures ethical standards, and guides the journal’s strategic direction. Associate editors manage specific subject areas—such as virology, antimicrobial stewardship, or zoonotic diseases—and coordinate the peer‑review process. An independent ethics committee monitors compliance with the Committee on Publication Ethics (COPE) guidelines, safeguarding integrity throughout the publication lifecycle Not complicated — just consistent. That alone is useful..
Open‑Access Model
EJMID follows a Gold Open‑Access model: all accepted articles are freely available online immediately upon publication, under a Creative Commons Attribution (CC‑BY) license. So naturally, authors (or their institutions) pay an Article Processing Charge (APC) that covers editorial handling, peer review, and digital archiving. This model maximizes visibility, citation potential, and real‑world impact, especially for clinicians in low‑resource settings who can access the latest findings without subscription barriers.
Indexing and Impact
The journal is indexed in major bibliographic databases such as PubMed/MEDLINE, Scopus, Web of Science, and Embase, ensuring discoverability by researchers worldwide. But 2) reflects a strong citation record, while alternative metrics (Altmetric score, downloads) highlight broader societal reach. Its Impact Factor (currently around 4.The combination of rigorous peer review, rapid turnaround (average 21 days to first decision), and open access makes EJMID a competitive venue for high‑impact work.
Step‑by‑Step Submission Process
1. Preparing the Manuscript
- Follow the Author Guidelines: Use the journal’s template (Microsoft Word or LaTeX) and adhere to word limits (typically 4,000–5,000 words for original research). Include structured sections—Abstract, Introduction, Materials & Methods, Results, Discussion, Conclusions, and References.
- Craft a Concise Title: It should be informative, include key terms, and stay under 150 characters.
- Write a Structured Abstract: Summarize background, objectives, methods, main results, and significance in ≤250 words.
- Select Keywords: Choose 4–6 MeSH‑compatible keywords that capture the core topics (e.g., “antimicrobial resistance”, “CRISPR‑Cas”, “nosocomial infection”).
2. Ethical Considerations
- Human Subjects: Provide Institutional Review Board (IRB) approval numbers and a statement confirming informed consent.
- Animal Studies: Include compliance with the ARRIVE guidelines and details of ethical committee approval.
- Data Availability: Deposit raw data in a recognized repository (e.g., Zenodo, NCBI) and cite the DOI in the manuscript.
3. Online Submission
- Create an Account on the journal’s manuscript management system (e.g., Editorial Manager).
- Upload Files: Manuscript, cover letter, figures (high‑resolution TIFF/PNG), tables (editable Excel), and supplementary material.
- Suggest Reviewers: Provide up to five potential reviewers with expertise aligned to your study; avoid conflicts of interest.
4. Peer Review
- Initial Editorial Check: The editor screens for scope, completeness, and adherence to guidelines.
- External Review: Typically two to three independent experts evaluate scientific rigor, novelty, and ethical compliance.
- Decision: Options include Accept, Minor Revision, Major Revision, or Reject. Authors receive reviewer comments and are expected to respond point‑by‑point within 30 days for revisions.
5. Production
- Upon acceptance, the manuscript undergoes copy‑editing, typesetting, and author proofing.
- Open‑Access Publication: After payment of the APC, the article is assigned a DOI and posted online.
Real Examples
Example 1 – Novel Antimicrobial Peptide Against Acinetobacter
A 2023 study published in EJMID described the discovery of a synthetic antimicrobial peptide (AMP) that exhibited bactericidal activity against multidrug‑resistant Acinetobacter baumannii. In real terms, the researchers combined in silico peptide design with in vitro time‑kill assays and demonstrated a four‑log reduction in bacterial load within 2 hours. Importantly, the AMP retained efficacy in a murine pneumonia model, reducing lung bacterial counts by 98 % compared with untreated controls.
Most guides skip this. Don't.
Why it matters: This work illustrates how EJMID serves as a conduit for translational research that could reshape treatment options for nosocomial infections, a leading cause of morbidity in intensive care units across Europe Which is the point..
Example 2 – Surveillance of SARS‑CoV‑2 Variants in Wastewater
During the COVID‑19 pandemic, a collaborative European consortium published a series of surveillance reports in EJMID, tracking the emergence of SARS‑CoV‑2 variants through wastewater sequencing. By correlating viral RNA concentrations with clinical case numbers, the team provided early warnings of the Alpha and Delta waves weeks before clinical testing data surged.
Why it matters: The study underscores the journal’s role in disseminating public‑health intelligence, enabling policymakers to implement timely mitigation measures.
Example 3 – CRISPR‑Cas9 Editing of Clostridioides difficile Toxins
A 2022 article detailed the use of CRISPR‑Cas9 to knock out toxin genes (tcdA and tcdB) in C. In real terms, the edited strains showed dramatically reduced cytotoxicity in vitro and attenuated disease severity in a hamster model. difficile. The authors proposed a live‑attenuated vaccine strategy based on these findings.
Why it matters: This example highlights EJMID’s commitment to publishing innovative molecular approaches that could revolutionize vaccine development against challenging bacterial pathogens.
Scientific or Theoretical Perspective
The research featured in EJMID rests on several foundational scientific principles:
- Microbial Genetics and Evolution – Understanding how horizontal gene transfer, mutation, and selective pressure drive antimicrobial resistance informs both surveillance and therapeutic design.
- Host‑Pathogen Interactions – The interplay between microbial virulence factors and host immune responses is central to disease pathogenesis and vaccine efficacy.
- Systems Biology – Integrating genomics, transcriptomics, proteomics, and metabolomics enables a holistic view of microbial physiology and its response to interventions.
- Epidemiological Modeling – Quantitative models (e.g., SEIR, Bayesian hierarchical models) predict outbreak trajectories and evaluate control strategies, providing evidence for public‑health decisions.
By publishing studies that apply these theories, EJMID advances a mechanistic understanding that bridges bench science with bedside care. Worth adding, the journal encourages methodological rigor—such as appropriate statistical power calculations, validation of diagnostic assays, and transparent reporting of negative results—thereby strengthening the reproducibility of the field.
Common Mistakes or Misunderstandings
| Mistake | Why It Happens | How to Avoid It |
|---|---|---|
| Insufficient methodological detail | Authors assume readers can infer protocols. | Explicitly state IRB/animal‑ethics approval numbers in the Methods section and attach consent forms if required. |
| Neglecting ethical statements | Overlooking journal checklist or assuming ethics approval is implicit. | Review the journal’s APC policy early; apply for institutional discounts or waivers if eligible. |
| Citing non‑peer‑reviewed sources as primary evidence | Relying on preprints or conference abstracts without critical appraisal. | |
| Overloading the abstract | Trying to fit too much data, leading to a confusing summary. Now, | |
| Submitting figures with low resolution | Using screen‑capture images or compressed JPEGs. Now, | Export figures as 300‑dpi TIFF or PNG files; ensure axis labels are legible when printed at 8 cm width. |
| Misinterpreting the open‑access APC | Assuming the fee is optional or that waivers are unavailable. On top of that, | Provide step‑by‑step descriptions, include reagent catalog numbers, and attach supplementary protocols. |
By proactively addressing these pitfalls, authors increase the likelihood of a smooth review process and a successful publication.
Frequently Asked Questions
1. What is the typical time from submission to publication?
The journal aims for a first decision within 21 days after submission. Once a manuscript is accepted, the production phase (copy‑editing, typesetting, proofing) usually takes 3–4 weeks, after which the article is published online ahead of print.
2. Can I submit a manuscript that has been posted as a preprint?
Yes. EJMID accepts manuscripts that have been previously shared on recognized preprint servers (e.g., bioRxiv, medRxiv). Authors must disclose the preprint citation in the cover letter and make sure the manuscript complies with the journal’s originality criteria Simple, but easy to overlook. Which is the point..
3. Are there fee waivers for authors from low‑income countries?
The journal offers full or partial APC waivers for corresponding authors affiliated with institutions in World Bank‑designated low‑income economies. Applicants should submit a waiver request during the submission process, providing supporting documentation of institutional eligibility Surprisingly effective..
4. How are conflicts of interest handled?
All authors must complete a conflict‑of‑interest (COI) statement during submission, disclosing financial, personal, or professional relationships that could influence the work. The editorial office evaluates COI disclosures and may request additional clarification before proceeding with peer review.
5. Is there a limit to the number of figures or tables?
While there is no strict cap, the journal encourages concise presentation. Typically, up to six figures and four tables are acceptable without incurring extra charges. Additional items can be placed in supplementary material, which is also openly accessible.
6. Can I request a specific reviewer?
Authors may suggest potential reviewers, but the final selection rests with the editorial team to ensure impartiality. If an author wishes to exclude a particular expert (e.g., a direct competitor), they can indicate this in the cover letter.
Conclusion
The European Journal of Microbiology and Infectious Diseases stands as a premier conduit for high‑quality, open‑access research that spans the full continuum of microbiology and infectious‑disease science. On the flip side, its rigorous peer‑review process, broad thematic scope, and rapid publication timeline make it an attractive venue for investigators seeking to disseminate findings that can directly influence clinical practice, public‑health policy, and scientific understanding. By mastering the submission workflow, adhering to ethical standards, and avoiding common pitfalls, authors can maximize their chances of successful publication.
At the end of the day, the journal’s impact lies not only in the citation metrics it garners but in the real‑world consequences of the work it publishes—whether that be a new antimicrobial peptide that saves lives in intensive care units, a surveillance system that predicts pandemic waves, or a gene‑editing breakthrough that paves the way for novel vaccines. Engaging with EJMID, therefore, offers researchers a powerful platform to contribute to the collective fight against infectious diseases and to shape the future of global health That's the part that actually makes a difference..
